GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Asset Turnover

ATAI Life Sciences NV (ATAI Life Sciences NV) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. ATAI Life Sciences NV's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. ATAI Life Sciences NV's Total Assets for the quarter that ended in Mar. 2024 was $281.30 Mil. Therefore, ATAI Life Sciences NV's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. ATAI Life Sciences NV's annualized ROE % for the quarter that ended in Mar. 2024 was -45.91%. It is also linked to ROA % through Du Pont Formula. ATAI Life Sciences NV's annualized ROA % for the quarter that ended in Mar. 2024 was -37.99%.


ATAI Life Sciences NV Asset Turnover Historical Data

The historical data trend for ATAI Life Sciences NV's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Asset Turnover Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - 0.08 - -

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ATAI Life Sciences NV's Asset Turnover

For the Biotechnology subindustry, ATAI Life Sciences NV's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ATAI Life Sciences NV's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ATAI Life Sciences NV's Asset Turnover distribution charts can be found below:

* The bar in red indicates where ATAI Life Sciences NV's Asset Turnover falls into.



ATAI Life Sciences NV Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

ATAI Life Sciences NV's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.314/( (305.441+293.478)/ 2 )
=0.314/299.4595
=0.00

ATAI Life Sciences NV's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (293.478+269.121)/ 2 )
=0/281.2995
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


ATAI Life Sciences NV  (NAS:ATAI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

ATAI Life Sciences NV's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-106.852/232.753
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-106.852 / 0)*(0 / 281.2995)*(281.2995/ 232.753)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.2086
=ROA %*Equity Multiplier
=-37.99 %*1.2086
=-45.91 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

ATAI Life Sciences NV's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-106.852/281.2995
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-106.852 / 0)*(0 / 281.2995)
=Net Margin %*Asset Turnover
= %*0
=-37.99 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


ATAI Life Sciences NV Asset Turnover Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV (ATAI Life Sciences NV) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Executives
Florian Brand officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Anne Nagengast Johnson officer: Chief Accounting Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Sahil Kirpekar officer: Chief Business Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Stephen Bardin officer: Chief Financial Officer C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach director 158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali director 4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer director, 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Srinivas Rao officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp 10 percent owner C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014